Blog

Research updates, legislation changes, and analysis from the world of psychedelic science.

• How to read ClinicalTrials.gov phase labels: what Phase 1, 2 and 3 do-and do not-mean

  2026-09-24

  Phase labels describe parts of a drug-development research program. They do not establish that an intervention is approved, safe, effective for an individual, or available outside the study.

• What will the study measure? Read the outcomes before you read a headline

  2026-09-24

  An outcome measure describes what researchers plan to count or assess. Its title, description and time frame make a study claim much easier to check later.

• A trial map pin is a starting point: read the dates and eligibility in the source record

  2026-09-24

  A nearby marker and a future completion date can look promising. Here is a short way to check what the original ClinicalTrials.gov record actually says.

• What a ClinicalTrials.gov study status tells you-and what it doesn’t

  2026-09-24

  Recruiting, active but not recruiting, and completed describe different points in a study’s timeline. Learn how to compare study and location status without reading more into those labels than they say.

• What Executive Order 14401 says about psychedelic research and ibogaine

  2026-09-24

  Executive Order 14401 directs federal support for state psychedelic programs and sets conditional agency tasks. Its $50 million allocation is not ibogaine-only funding, and the order does not approve a treatment.

• Sponsor, study site and contact: which one do you need?

  2026-09-23

  An organisation name, a map marker and a study contact serve different purposes. Here is how to find the right details in the original record.

• How to tell a trial listing from study results

  2026-09-23

  A registered study describes a research plan. Learn where to look for results and how to keep the two separate.

• A guide to Psychoactive Map’s legislation layer

  2026-09-06

  The legislation layer helps you find source-linked records by place and compound. This guide explains its limited coverage, map colors, source details, and correction process.

• How to Participate in Psychedelic Clinical Trials

  2026-06-08

  ClinicalTrials.gov can help you find a study, but neither the registry nor PsychoactiveMap enrolls participants. Check official status, eligibility and contact details, then discuss risks, consent, time and costs with the study team and your clinician.

• Recruiting Phase 2 Trial Compares Group and Individual MDMA-Assisted Therapy for PTSD After October 7

  2026-03-31

  NCT07469098 is a recruiting, randomized, parallel, open-label phase 2 non-inferiority trial sponsored by Sheba Medical Center. It estimates 168 participants and completion in March 2029. No results are posted, and allocation is randomized rather than participant-selected.

• Proposed S. 4031 Would Create VA Innovative-Therapies Centers and Authorize $30M Annually

  2026-03-26

  Introduced S. 4031 would direct the VA to designate at least five innovative-therapies centers and authorize $30 million per fiscal year for research and education, subject to appropriations. The bill is not enacted and guarantees neither construction nor funding.